BSG005
Invasive Fungal Infections (Candida, Aspergillus, Fusarium, Mucor, Cryptococcus)
Key Facts
About Biosergen
Biosergen is a clinical-stage biotechnology company focused on revolutionizing the treatment of invasive fungal diseases (IFDs) through genetic engineering. Its lead asset, BSG005, is a novel polyene antifungal that has demonstrated a superior safety profile in a Phase 1 study, with no significant side effects observed, addressing the critical nephrotoxicity that plagues current standards of care. The company's strategy leverages a proprietary platform to re-engineer polyene macrolides, aiming to capture a significant share of the growing antifungal market driven by rising immunocompromised populations and increasing drug resistance. Biosergen is advancing BSG005 into proof-of-concept studies with a key partnership in India and holds global commercial rights.
View full company profile